

## Medicine Shortage Communication

<Date>

### **Victoza 6 mg/mL solution for injection in pre-filled pen (liraglutide): Risk of supply shortage due to marketing cessation (discontinuation)**

Dear Healthcare Professional,

Novo Nordisk <affiliate to include country specific information to reflect global or local company name> in agreement with the European Medicines Agency and the <National Competent Authority> is notifying healthcare professionals about the marketing-cessation (discontinuation) of Victoza (liraglutide) in all EU/EEA countries. This discontinuation may lead to short-term intermittent shortages in some countries.

#### ***Overview of situation***

- **Novo Nordisk will discontinue the marketing of Victoza across the EU/EEA by the end of 2026.**
- **Due to the marketing cessation, there may be a risk of short-term intermittent shortages in some countries until the product is no longer marketed.**
- **Timelines for the discontinuation vary from country to country, but will be completed in all EU member states by December 2026.**
- **The discontinuation in <insert country name> <will occur> <occurred> before/by/in <insert date>.**
- **The marketing cessation is for commercial reasons and not a consequence of any safety or quality related issue.**

#### ***Mitigation measures***

Novo Nordisk is engaging with the European Medicines Agency and the [National Competent Authority] on mitigation measures.

Regulatory authorities, physicians, healthcare providers and patient organisations are being informed to help ensure patients transition safely to alternative options for continuity of care.

Patients need to be switched to an alternative treatment in time to avoid the risk of missing doses, which may lead to serious clinical consequences.

---

## **Healthcare professionals (HCPs) should consider the following mitigation measures:**

- No new patients should be started on Victoza.
- HCPs should switch all patients who are currently on Victoza to alternative GLP-1 analogues or other alternative medication based on existing guidance and clinical judgement.
- HCPs are requested to follow the relevant summary of product characteristics (SmPCs) of the alternative products for dosing recommendations while switching patients to alternative products.
- HCPs are requested to provide clear instructions of usage to the patient, if switched to alternative GLP-1 analogue or other alternative.
- Close glucose monitoring is recommended during the switch to another type or brand of alternative GLP-1 analogue or other alternative and patients should be fully informed about any relevant changes.

## ***Background information***

Victoza<sup>1</sup> is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- as monotherapy when metformin is considered inappropriate due to intolerance or contra indications;
- in addition to other medicinal products for the treatment of diabetes  
[affiliate to include country specific **indication** information]. [affiliate to include country specific **presentation** information].

For up-to-date information on the availability of Victoza and the alternatives in a particular EU/EEA country, consult the National Competent Authority.

## ***Company contact point***

Further information can be obtained by contacting <local Novo Nordisk affiliate contact details to be added by affiliate>

Yours sincerely,

Medical Director

## ***Annex***

References:

1. [Victoza | European Medicines Agency \(EMA\)](#)

## **Communication Plan for Medicine Shortage Communication**

MSC COMMUNICATION PLAN	
<b>Medicinal product(s)/active substance(s)</b>	Victoza (liraglutide)
<b>Marketing authorisation holder(s)</b>	Novo Nordisk A/S
<b>Purpose of the communication</b>	Inform healthcare professionals on the discontinuation of Victoza and mitigation measures to manage the marketing cessation.
<b>MSC recipients</b>	Target group for this letter includes specialists who treat patients with diabetes (e.g. endocrinologists, diabetologists, specialists in internal medicine), general practitioners/family physicians, pharmacists, diabetes nurses in all EU/EEA countries in which Victoza is marketed. The target group can be further defined at national level, in agreement with the respective national competent authorities.
<b>Member States where the MSC will be distributed</b>	All EU/EEA countries where Victoza is marketed
<b>Timetable</b> <i>[Delete steps which are not applicable]</i>	
<b>MSC and communication plan (in English) agreed by SPOC WP</b>	14 August 2025
<b>MSC and communication plan (in English) agreed by MSSG</b>	22 August 2025
<b>Submission of translated MSCs to the national competent authorities for review</b>	29 August 2025
<b>Agreement of translations by national competent authorities</b>	02 September 2025
<b>Dissemination of MSC</b>	by 05 September 2025